We can’t show the full text here under this license. Use the link below to read it at the source.
Drug treatment for metabolic dysfunction-associated steatotic liver disease: Progress and direction
Drug treatments for fatty liver disease linked to metabolism: progress and future directions
AI simplified
Abstract
Resmetirom is the first officially approved drug for treating metabolic dysfunction-associated steatohepatitis with fibrosis.
- Metabolic dysfunction-associated steatotic liver disease () is the most common chronic liver disease worldwide.
- Early diagnosis and treatment of metabolic dysfunction-associated steatohepatitis () may reduce complications.
- Pharmacotherapeutics for MASH face challenges due to the complexity of its pathogenesis.
- Investigational agents are targeting key pathways to potentially reduce steatohepatitis and fibrosis.
- Other agents, including peroxisome proliferator-activated receptor agonists and glucagon-like peptide-1 analogs, are in development and awaiting approval.
AI simplified
Key numbers
1
Approval of Resmetirom
First FDA-approved drug for treatment
25.9%
Efficacy of Resmetirom
Percentage of patients achieving resolution without worsening fibrosis at 80 mg dose
29.9%
Efficacy of Resmetirom
Percentage of patients achieving resolution without worsening fibrosis at 100 mg dose